<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pmedpharm</journal-id><journal-title-group><journal-title xml:lang="ru">Фармация и фармакология</journal-title><trans-title-group xml:lang="en"><trans-title>Pharmacy &amp; Pharmacology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2307-9266</issn><issn pub-type="epub">2413-2241</issn><publisher><publisher-name>Pyatigorsk Medical and Pharmaceutical Institute - branch of Volgograd State Medical Univer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.19163/2307-9266-2020-8-4-242-254</article-id><article-id custom-type="elpub" pub-id-type="custom">pmedpharm-729</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ФАРМАЦЕВТИЧЕСКАЯ И ТОКСИКОЛОГИЧЕСКАЯ ХИМИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PHARMACEUTICAL AND TOXICOLOGICAL CHEMISTRY</subject></subj-group></article-categories><title-group><article-title>ИЗУЧЕНИЕ СТАБИЛЬНОСТИ СУБСТАНЦИИ 3-[2-(4-ФЕНИЛ-1- ПИПЕРАЗИНО)-2-ОКСОЭТИЛ]ХИНАЗОЛИН-4(3Н)-ОНА В СТРЕССОВЫХ УСЛОВИЯХ</article-title><trans-title-group xml:lang="en"><trans-title>STUDY OF THE STABILITY OF THE SUBSTANCE 3-[2-(4-PHENYL-1-PIPERAZINO)-2-OXOETHYL]QUINAZOLINE-4(3Н)-ONE UNDER STRESSFUL CONDITIONS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7447-8328</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гендугов</surname><given-names>Т. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Gendugov</surname><given-names>T. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гендугов Тембот Алимович – аспирант кафедры неорганической, физической и коллоидной химии </p><p>357532, г. Пятигорск, пр. Калинина, 11</p></bio><bio xml:lang="en"><p>Tembot A. Gendugov – Post-graduate student of the Department of Inorganic, Physical and Colloidal Chemistry </p><p>11, Kalinin Ave., Pyatigorsk, 357532</p></bio><email xlink:type="simple">timbirlei2008@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1715-0350</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Глушко</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Glushko</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Глушко Александр Алексеевич – кандидат фармацевтических наук, доцент кафедры неорганической, физической и коллоидной химии </p><p>357532, г. Пятигорск, пр. Калинина, 11</p></bio><bio xml:lang="en"><p>Aleksandr A. Glushko – Candidate of Sciences (Pharmacy), Associate Professor of the Department of Inorganic, Physical and Colloidal Chemistry </p><p>11, Kalinin Ave., Pyatigorsk, 357532</p></bio><email xlink:type="simple">alexander.glushko@lcmmp.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4721-0959</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Озеров</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Ozerov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Озеров Александр Александрович – профессор, доктор химических наук, заведующий кафедрой фармацевтической и токсикологической химии </p><p>400131, г. Волгоград, площадь Павших Борцов, 1</p></bio><bio xml:lang="en"><p>Alexander A. Ozerov – Doctor of Sciences (Chemistry), Professor, the Head of the Department of Pharmaceutical and Toxicological Chemistry </p><p>1, Pavshikh Bortsov Sq., Volgograd, 400131</p></bio><email xlink:type="simple">prof_ozerov@yahoo.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7806-2805</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Щербакова</surname><given-names>Л. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Shcherbakova</surname><given-names>L. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Щербакова Лариса Ивановна – доцент, кандидат фармацевтических наук, зав. кафедрой неорганической, физической и коллоидной химии </p><p>357532, г. Пятигорск, пр. Калинина, 11</p></bio><bio xml:lang="en"><p>Larisa I. Shcherbakova – Candidate of Sciences (Pharmacy), Associate Professor, the Head of the Department of Inorganic, Physical and Colloidal Chemistry </p><p>11, Kalinin Ave., Pyatigorsk, 357532</p></bio><email xlink:type="simple">shcherbakovali@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Пятигорский медико-фармацевтический институт – филиал ФГБОУ ВО ВолгГМУ Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pyatigorsk Medical and Pharmaceutical Institute – branch of Volgograd State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Волгоградский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Volgograd State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>31</day><month>01</month><year>2021</year></pub-date><volume>8</volume><issue>4</issue><fpage>242</fpage><lpage>254</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гендугов Т.А., Глушко А.А., Озеров А.А., Щербакова Л.И., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Гендугов Т.А., Глушко А.А., Озеров А.А., Щербакова Л.И.</copyright-holder><copyright-holder xml:lang="en">Gendugov T.A., Glushko A.A., Ozerov A.A., Shcherbakova L.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmpharm.ru/jour/article/view/729">https://www.pharmpharm.ru/jour/article/view/729</self-uri><abstract><p>Цель работы – изучение стабильности новой фармацевтической субстанции 3-[2-(4-фенил-1-пиперазино)-2-оксоэтил]хиназолин-4(3Н)-она под воздействием стресс-условий.</p><sec><title>Материалы и методы</title><p>Материалы и методы. Исследование выполнено в соответствии с рекомендациями руководства ICH. Объектом исследования было ранее не изученное производное хиназолин-4(3Н)-она: 3-[2-(4-фенил-1-пиперазино)-2-оксоэтил] хиназолин-4(3Н)-он, синтезированное в Волгоградском государственном медицинском университете. Было использовано лабораторное оборудование: ВЭЖХ-хроматограф, ВЭЖХ-МС, центрифуга, электронные весы, рН-метр, термостат, лабораторные фильтры. Вычислительный эксперимент проводился на компьютере с процессором Intel Xeon E3-1230 с использованием программ ORCA 4.1. и GROMACS 2019.</p></sec><sec><title>Результаты</title><p>Результаты. Изучено и определено влияние неблагоприятных факторов внешней среды, таких как: высокая температура, свет, действие окислителей, гидролиза в кислой и щелочной среде на стабильность исследуемого вещества. Результаты компьютерного прогнозирования стабильности были подтверждены с помощью ВЭЖХ и ВЭЖХ-МС, а также определены продукты деструкции субстанции в стрессовых условиях. Проведенные исследования показали, что исследуемое вещество стабильно к воздействию УФ-облучения при длине волны 365 нм, повышенной температуры (80°C), действию окислителей и нестабильно к гидролизу: в щелочной среде натрия гидроксида 1М происходит разрыв по амидной группе с образованием 2-(4-оксохиназолин-3-ил)уксусной кислоты и 1-фенилпиперазина; а в кислой среде кислоты хлористоводородной 1М также происходит деструкция, но она значительно снижается, предположительно, за счет протонирования и стабилизации третичных атомов азота в молекуле.</p></sec><sec><title>Заключение</title><p>Заключение. Проведенные исследования позволяют сделать вывод о том, что исследуемая субстанция 3-[2-(4-фенил-1-пиперазино)-2-оксоэтил]хиназолин-4(3Н)-он стабильна к агрессивным факторам внешней среды, за исключением гидролиза в щелочной среде, что в дальнейшем будет учитываться при составлении нормативной документации этой фармацевтической субстанции.</p></sec></abstract><trans-abstract xml:lang="en"><p>The aim of the research was to study the stability of a new pharmaceutical substance 3-[2-(4-phenyl-1-piperazino)-2-oxoethyl]quinazoline-4(3Н)-one under stress conditions.</p><sec><title>Materials and methods</title><p>Materials and methods. The study was conducted in accordance with the recommendations of the ICH guidelines. The object of the study was a previously unknown derivative of quinazoline-4(3H)-one: 3-[2-(4-phenyl-1-piperazino)-2-oxoethyl] quinazoline-4(3Н)-one synthesized in Volgograd state medical university. The following laboratory equipment was used: HPLC chromatograph, HPLC-MS, centrifuge, electronic scales, pH meter, thermostat, laboratory filters. The computational experiment was conducted on a computer with an Intel Xeon E3-1230 processor using the programs ORCA 4.1. and GROMACS 2019.</p></sec><sec><title>Results</title><p>Results. The influence of the most unfavorable environmental factors, such as high temperature, light, oxidants, hydrolysis in acidic and alkaline environments, affect the stability of the test substance. The results of the computer-based stability prediction were confirmed by HPLC and HPLC-MS, and the degradation products of the substance under stressful conditions were determined. The conducted studies showed that the test substance is stable to UV radiation at the wavelength of 365 nm, at the elevated temperature (80°C), to the action of oxidants. But it is unstable to hydrolysis: in an alkaline medium of sodium hydroxide 1M, a break in the amide group occurs with the formation of 2-(4-oxoquinazoline-3-yl)acetic acid and 1-phenylpiperazine. And in an acidic environment, hydrochloric acid 1M is also destroyed, but it is significantly reduced, presumably due to the protonation and stabilization of tertiary nitrogen atoms in the molecule.</p></sec><sec><title>Conclusion</title><p>Conclusion. The conducted research makes it possible to conclude that the test substance 3-[2-(4-phenyl-1-of piperazino)-2-oxoethyl]quinazoline-4(3Н)-one is stable to aggressive environmental factors, with the exception of hydrolysis in an alkaline environment that will be further considered in the preparation of regulatory documents for this pharmaceutical substance.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>производное хиназолин-4(3Н)-она</kwd><kwd>фармацевтическая субстанция</kwd><kwd>стресс-тестирование</kwd><kwd>моделирование стресс-тестов</kwd><kwd>термолиз</kwd><kwd>фотолиз</kwd><kwd>гидролиз</kwd><kwd>высокоэффективная жидкостная хроматография</kwd><kwd>фотостабильность</kwd><kwd>термостабильность</kwd><kwd>GROMACS</kwd><kwd>ORCA</kwd></kwd-group><kwd-group xml:lang="en"><kwd>quinazoline-4(3H)-one derivative</kwd><kwd>pharmaceutical substance</kwd><kwd>stress testing</kwd><kwd>stress test modeling</kwd><kwd>thermolysis</kwd><kwd>photolysis</kwd><kwd>hydrolysis</kwd><kwd>high-performance liquid chromatography</kwd><kwd>photostability</kwd><kwd>thermalstability</kwd><kwd>GROMACS</kwd><kwd>ORCA</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Данная работа не имела финансирования от сторонних организаций</funding-statement><funding-statement xml:lang="en">This work did not have funding from outside organizations</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Государственная Фармакопея Российской Федерации. Изд. XIV. Т. 1. – М., 2018. [Электронный ресурс]. http://feml.scsml.rssi.ru/feml</mixed-citation><mixed-citation xml:lang="en">Gosudarstvennaya pharmakopeya Rossiiskoi Federatsii [State Pharmacopoeia of the Russian Federation]. In 14 Vol. [cited 2019 Dec 27]. Available from: http:// femb.ru/femb/pharmacopea.php.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">ICH guidelines, Q1A (R2): Stability Testing of New Drug Substances and Products (Revision 2), International Conference on Harmonization; 2003. [Электронный ресурс]. – https://www.ema.europa.eu/en/documents/scientific–guideline/ich-q-1-r2-stability-testing-new-drugsubstances-products-step-5_en.pdf</mixed-citation><mixed-citation xml:lang="en">ICH guidelines, Q1A (R2): Stability Testing of New Drug Substances and Products (Revision 2), International Conference on Harmonization [cited 2019 Dec 20]. Available from: https://www.ema.europa.eu/en/documents/ scientific–guideline/ich-q-1-r2-stability-testing-new-drugsubstances-products-step-5_en.pdf</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">ICH Guidance, Q1C: Stability Testing for New Drug Dosage Forms, International Conference on Harmonization. 1996. [Электронный ресурс]. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-c-stability-testingrequirements-new-dosage-forms-step-5_en.pdf</mixed-citation><mixed-citation xml:lang="en">ICH Guidance, Q1C: Stability Testing for New Drug Dosage Forms, International Conference on Harmonization [cited 2019 Dec 12]. Available from: https://www.ema.europa.eu/en/ documents/scientific-guideline/ich-q-1-c-stabilitytestingrequirements-new-dosage-forms-step-5_en.pdf</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Existing Active Ingredients and Related Finished Products (CPMP/QWP/122/02 Rev. 1 corr), 2003. [Электронный ресурс]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003466.pdf</mixed-citation><mixed-citation xml:lang="en">Existing Active Ingredients and Related Finished Products (CPMP/QWP/122/02 Rev. 1 corr) [cited 2019 Dec 25]. Available from: http://www.ema.europa.eu/docs/en_ GB/document_library/Scientific_guideline/2009/09/WC500003466.pdf</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">ICH Guidance, Q1B: Photostability Testing of New Drug Substances and Products, International Conference on Harmonization, 1998. [Электронный ресурс] https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-b-photostability-testing-new-active-substancesmedicinal-products-step-5_en.pdf</mixed-citation><mixed-citation xml:lang="en">ICH Guidance, Q1B: Photostability Testing of New Drug Substances and Products, International Conference on Harmonization [cited 2019 Dec 27]. Available from: https://www.ema.europa.eu/en/documents/scientificguideline/ich-q-1-b-photostability-testing-new-activesubstances-medicinal-products-step-5_en.pdf</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">FDA Guidance for Industry, INDs for Phase II and III Studies – Chemistry, Manufacturing and Controls Information, Food and Drug Administration, 2003. [Электронный ресурс]. – https://www.fda.gov/media/70822/download</mixed-citation><mixed-citation xml:lang="en">Food and Drug Administration, FDA Guidance for Industry, INDs for Phase II and III Studies – Chemistry, Manufacturing and Controls Information [cited 2019 Dec 22]. Available from: https://www.fda.gov/media/70822/download</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Klauda, J.B., Venable, R.M., Freites, J.A., O’Connor, J.W., Tobias, D.J., Mondragon-Ramirez, C., Vorobyov, I., MacKerell, Jr., A.D., Pastor R.W. Update of the CHARMM All-Atom Additive Force Field for Lipids: Validation on Six Lipid Types // Journal of Physical Chemistry B. – 2010. – V. 114, No23. – Р. 7830–7843. DOI: 10.1021/jp101759q</mixed-citation><mixed-citation xml:lang="en">Klauda JB, Venable RM, Freites JA, O’Connor JW, Tobias DJ, Mondragon-Ramirez C, et al. Update of the CHARMM All-Atom Additive Force Field for Lipids: Validation on Six Lipid Types. Journal of Physical Chemistry B. 2010;114(23):7830–43. DOI:10.1021/jp101759q</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Abraham M.J., Murtola T., Schulz R., Páll S., Smith J.C., Hess B., Lindahl E. GROMACS: High performance molecular simulations through multi–level parallelism from laptops to supercomputers // SoftwareX. – 2015. – V. 1–2. – P. 19–25. DOI: 10.1016/j.softx.2015.06.001.</mixed-citation><mixed-citation xml:lang="en">Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B, et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1–2:19–25. DOI:10.1016/j.softx.2015.06.001.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Zoete V., Cuendet M. A., Grosdidier A., Michielin O. SwissParam: a Fast Force Field Generation Tool For Small Organic Molecules // Journal of Computational Chemistry. – 2011. – V. 32, No 11. – P. 2359–2368. DOI: 10.1002/jcc.21816.</mixed-citation><mixed-citation xml:lang="en">Zoete V, Cuendet MA, Grosdidier A, Michielin O. SwissParam: a Fast Force Field Generation Tool For Small Organic Molecules. Journal of Computational Chemistry. 2011;32(11):2359–68. DOI:10.1002/ jcc.21816.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Braga C., Travis K. P. A configurational temperature Nosé– Hoover thermostat // The Journal of Chemical Physics.–2005. – V. 123, No 11. – P.123. DOI: 10.1063/1.2013227.</mixed-citation><mixed-citation xml:lang="en">Braga C., Travis K. P. A configurational temperature Nosé – Hoover thermostat. The Journal of Chemical Physics. 2005;123(11):123. DOI:10.1063/1.2013227.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Neese F. Software update: The ORCA program system, version 4.0 // Wiley Interdisciplinary Reviews: Computational Molecular Science. – 2017. – Vol. 8, No 1.– P. e1327. DOI: 10.1002/wcms.1327.</mixed-citation><mixed-citation xml:lang="en">Neese F. Software update: The ORCA program system, version 4.0. Wiley Interdisciplinary Reviews: Computational Molecular Science. 2017;8(1):e1327. DOI: 10.1002/wcms.1327.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Bäcktorp C., Örnskov E., Ottosson J., Evertsson E., Remmelgas J., Broo A. Experimental and Quantum Chemical Evaluations of Pyridine Oxidation Under Drug Development Stress Test Conditions // Journal of Pharmaceutical Sciences. –2015. – V. 104 (12). – P. 4355–4364. DOI: 10.1002/jps.24685</mixed-citation><mixed-citation xml:lang="en">Bäcktorp C, Örnskov E, Ottosson J, Evertsson E, Remmelgas J, Broo A. Experimental and Quantum Chemical Evaluations of Pyridine Oxidation Under Drug Development Stress Test Conditions. Journal of Pharmaceutical Sciences. 2015;104(12):4355– 43. DOI:10.1002/jps.24685</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Szepesi G., Gazdag M., Mihályfi K. Selection of high– performance liquid chromatographic methods in pharmaceutical analysis // Journal of Chromatography A. – 1991. – V. 464. – P. 265–278. DOI:10.1016/s0021-9673(00)94245-6</mixed-citation><mixed-citation xml:lang="en">Szepesi G, Gazdag M, Mihályfi K. Selection of high – performance liquid chromatographic methods in pharmaceutical analysis. Journal of Chromatography A. 1991;464:265–278. DOI:10.1016/s0021- 9673(00)94245-6.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Gazdag M., Szepesi G., Szeleczki E. Selection of high–performance liquid chromatographic methods in pharmaceutical analysis // Journal of Chromatography A. – 1988. – V. 454. – P. 83–94. DOI:10.1016/s0021-9673(00)88604-5</mixed-citation><mixed-citation xml:lang="en">Gazdag M, Szepesi G, Szeleczki E. Selection of high–performance liquid chromatographic methods in pharmaceutical analysis. Journal of Chromatography A. 1988;454:83–94. DOI:10.1016/s0021-9673(00)88604-5.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Carr G.P., Wahlich J.C. A practical approach to method validation in pharmaceutical analysis // Journal of Pharmaceutical and Biomedical Analysis. – 1990. – V. 8 (8–12). – P. 613–618. DOI:10.1016/0731-7085(90)80090-c</mixed-citation><mixed-citation xml:lang="en">Carr GP, Wahlich JC. A practical approach to method validation in pharmaceutical analysis. Journal of Pharmaceutical and Biomedical Analysis. 1990;8(8–12):613–618. DOI:10.1016/0731-7085(90)80090-c.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Jenke D.R. Chromatographic method validation: a review of common practices and procedures // Journal of Liquid Chromatography &amp; Related Technologies. – 1996. – V. 19 (5). – P. 719–736. DOI: 10.1080/10826079608005533</mixed-citation><mixed-citation xml:lang="en">Jenke D.R. Chromatographic method validation: a review of common practices and procedures. Journal of Liquid Chromatography &amp; Related Technologies. 1996;19(5): 719–736. DOI:10.1080/10826079608005533.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Iram F., Iram H., Iqbal A., Husain A. Forced Degradation Studies // Journal of Analytical &amp; Pharmaceutical Research. – 2016. – V. 3, No 6. – P. 73. DOI: 10.15406/japlr.2016.03.00073</mixed-citation><mixed-citation xml:lang="en">Iram F, Iram H, Iqbal A, Husain A. Forced Degradation Studies. Journal of Analytical &amp; Pharmaceutical Research. 2016;3(6):73. DOI: 10.15406/ japlr.2016.03.00073.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Blessy M., Patel R.D., Prajapati P.N., Agrawal Y.K. Development of forced degradation and stability indicating studies of drugs – A review // Journal of Pharmaceutical Analysis. – 2014. – V. 4, No 3. – P. 159–165. DOI: 10.1016/j.jpha.2013.09.003</mixed-citation><mixed-citation xml:lang="en">Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability indicating studies of drugs – A review. Journal of Pharmaceutical Analysis. 2014;4(3):159–165. DOI:10.1016/j.jpha.2013.09.003.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Alsante K.M., Ando A., Brown R., et al. The role of degradant profiling in active pharmaceutical ingredients and drug products // Advanced Drug Delivery Reviews. – 2007. – V. 59, No1. – P. 29–37. DOI: 10.1016/j.addr.2006.10.006</mixed-citation><mixed-citation xml:lang="en">Alsante KM, Ando A, Brown R, Ensing J, Hatajik T, Kong W, et al. The role of degradant profiling in active pharmaceutical ingredients and drug products. Advanced Drug Delivery Reviews. 2007;59(1):29–37. DOI:10.1016/j.addr.2006.10.006.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Piechocki J.T., Thoma K. Pharmaceutical Photostability and Stabilization Technology, Informa Healthcare. – CRC Press, publ. 2019. – 445p.</mixed-citation><mixed-citation xml:lang="en">Piechocki JT, Thoma K. Pharmaceutical Photostability and Stabilization Technology. 1th ed. Informa Healthcare. CRC Press, 2019.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Singh R, Rehman Z. Current trends in forced degradation study for pharmaceutical product development. Journal of Pharmaceutical Education and Research. 2012;3(1):54–63.</mixed-citation><mixed-citation xml:lang="en">Singh R, Rehman Z. Current trends in forced degradation study for pharmaceutical product development. Journal of Pharmaceutical Education and Research. 2012;3(1):54–63.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
